Short Interest in Aclarion, Inc. (NASDAQ:ACON) Increases By 379.3%

Aclarion, Inc. (NASDAQ:ACON) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 148,674 shares, a growth of 379.3% from the December 31st total of 31,021 shares. Approximately 17.6% of the shares of the stock are sold short. Based on an average daily volume of 4,557,681 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 4,557,681 shares, the days-to-cover ratio is currently 0.0 days. Approximately 17.6% of the shares of the stock are sold short.

Aclarion Trading Down 1.1%

Shares of NASDAQ:ACON opened at $3.64 on Wednesday. The company has a market cap of $3.09 million, a price-to-earnings ratio of -0.24 and a beta of 1.44. Aclarion has a 12 month low of $3.61 and a 12 month high of $562.68. The company has a 50-day moving average price of $5.47 and a 200-day moving average price of $6.80.

Aclarion (NASDAQ:ACON) last posted its earnings results on Wednesday, November 12th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.64) by ($0.29). Aclarion had a negative net margin of 10,908.50% and a negative return on equity of 67.53%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. As a group, research analysts forecast that Aclarion will post -263.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Wall Street Zen upgraded shares of Aclarion to a “hold” rating in a research report on Saturday, December 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.